Skip to main content
. 2012 Mar 1;86(3):417–425. doi: 10.4269/ajtmh.2012.10-0415

Figure 2.

Figure 2.

Impact of vaccination cost and vaccine efficacy on the incremental cost-effectiveness ratio (ICER)* assumes 30% minor vaccine side effect probability, 75% treatment probability, baseline infection risk, and use of amphotericin B for treatment.